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Abstract
The evaluation and use of patient reported outcome (PRO) measures requires detailed
understanding of the meaning of the outcome of interest. The Food and Drug Administration
(FDA) recently presented its draft guidance and view on the use of PRO measures as endpoints in
clinical trials. One section of the guidance document specifically deals with advice about the use of
the minimal important difference (MID) that we redefined as the smallest difference in score in the
outcome of interest that informed patients or informed proxies perceive as important. The advice,
however, is short, indeed much too short. We believe that expanding the section and making it
more specific will benefit all stakeholders: patients, clinicians, other clinical decision makers, those
designing trials and making claims, payers and the FDA.
There is no "gold standard" methodology of estimating the MID or achieving the meaningfulness of
clinical trial results based on patient reported outcomes. There are many methods of estimating
the MID usually grouped into two distinct categories: anchor-based methods, that examine the
relationship between scores on the target instrument and some independent measure, and
distribution-based methods resorting to the statistical characteristics of the obtained scores.
Estimation of an MID and interpretation of clinical trial results that present patient important
outcomes is demanding but vital for informing the decision to recommend approve a given
intervention. Investigators are encouraged to use reliable and valid methods to achieve
meaningfulness of their results, preferably those that rely on patients to estimate what constitutes
a minimal important, small, moderate, or large difference. However, acquiring the meaningfulness
of PRO measures transcends beyond a concept of the MID and we advocate that dichotomizing
the scores of patient-reported outcome measures facilitate interpretability of clinical trial results
for those who need to understand trial results after a labelling claim has been granted. Irrespective
of the strategy investigators use to estimate these values, from the individual patient perspective it
is much more relevant if investigators report both the estimated thresholds and the proportion of
patients achieving that benefit.
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Background
The Food and Drug Administration (FDA) presents its
draft guidance and its view on the use of patient-reported
outcome (PRO) measures as endpoints in clinical trials in
this issue of Health and Quality of Life Outcomes [1]. It
includes information on how sponsors could use study
results based on these measures to support claims in their
product labelling that carries important implications for
study design and interpretation of the findings [1]. The
advice, however, is short, indeed we believe much too
short.
The evaluation and use of PRO measures requires detailed
understanding of the meaning of the outcome of interest.
Achieving this understanding presents a considerable
challenge even for seemingly straightforward dichoto-
mous outcomes such as stroke, myocardial infarction, or
death [2,3]. The complexity increases with the realization
that no binary outcome is truly unambiguous: deaths can
be painful or painless, strokes can be mild or severe, and
myocardial infarctions can be large and complicated or
small and uncomplicated. The way the investigators
present the results of clinical trials also influences clini-
cians' willingness to undertake a specific action [4-7]. This
problem becomes even more complex when one consid-
ers that different patients may place a different value on a
particular benefit (inter-individual variation) or even the
same patient may place a different value on the same ben-
efit (intra-individual variation), depending on the circum-
stances. These difficulties occur despite the ease with
which one can generally communicate an event such as
stroke or death.
The challenges increase further, when one faces PRO
scores expressed in unfamiliar ordinal or continuous
scales. Even those familiar with the concept of PRO or
health related quality of life (HRQL) assessment generally
have no intuitive notion of the significance of a change in
score of a particular magnitude on most instruments that
investigators use to measure the severity of outcomes such
as stroke or myocardial infarction.
Therefore, one can frame the problem as an issue of inter-
pretability: what changes in score correspond to trivial,
small, moderate, or large patient benefit or harm [8].
The FDA guidance dedicates section IV.C.4 (Choice of
Methods for Interpretation) to this particular issue and
describes "some of the methods that have helped spon-
sors and the FDA interpret clinical trial results based on
PRO endpoints". We believe that expanding this section
and making it more specific will benefit all stakeholders:
patients, clinicians, other clinical decision makers, those
designing trials and making claims, payers and the FDA.
Discussion
The Authors of the guidance focused their attention on the
minimal important difference (MID). Therefore, we will
centre our attention on 4 questions related to the MID: 1)
what is the MID; 2) why is the MID important; 3) how to
estimate the MID; and 4) when the MID is the proper
approach to claiming efficacy and how can it be used by
clinicians to understand claims based on clinical trials
using PRO measures. Acquiring the meaningfulness of
PRO measures transcends beyond a concept of the MID,
so we will supplement the discussion about questions 3
and 4 with a consideration on other related approaches
investigators used to achieve interpretability of PRO
instruments.
To place the interpretation of PRO measure scores in con-
text, before we address the specific issues, we suggest, that
the reader conceptualizes these scores as any continuous
(e.g. visual analogue pain scale, height) or discrete, in par-
ticular ordinal (e.g. stage 1 through stage 4 cancer, severity
of pain: none, mild, moderate, severe) variable. It may
also be helpful to visualize the PRO score as a surrogate
outcome measure that needs some "mapping" into
another meaningful, patient-important outcome in order
to gain interpretability.
What is the minimal important difference?
Definition
The FDA document does not provide a sensu stricto defini-
tion of the MID obtained with a PRO measure and con-
fines itself to the notion of "meaningful change" or "effect
that might be considered important" [1]. We suggested
that the MID be the smallest difference in score in the out-
come of interest that informed patients or informed prox-
ies perceive as important, either beneficial or harmful,
and that would lead the patient or clinician to consider a
change in the management [9,10].
We place a greater weight on the preferences of informed
patients than of informed proxies (including clinicians) in
determining the MID. We should consider the MID esti-
mates of informed proxies only if informed patients can-
not make decisions about the management of their
disease or if patients prefer informed proxies, including
clinicians, to make these decisions. It is also important to
bear in mind that any change in management will depend
on the associated downsides, including harm, cost and
inconvenience.
Implications
This definition of the MID precludes making its estimates
for outcomes that are remote from those important, in
themselves, to patients, such as spirometry or laboratory
exercise capacity. It also suggests that only if one had rea-
son to question the reliability or accuracy of data fromHealth and Quality of Life Outcomes 2006, 4:69 http://www.hqlo.com/content/4/1/69
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patients would one rely on proxies to provide estimates of
the MID. If one accepts that PRO measurement must be
fundamentally patient-important, the first choice for
establishing the MID should be a patient-based approach.
Relative to patients, clinicians may overemphasize treat-
ment effects [11] and agreement between patients and
proxies in rating the PROs is far from perfect [12-15]. To
be maximally informative, representative samples of
informed patients or if necessary their proxies should pro-
vide estimates of the MID.
Why do we need a MID?
There are several reasons for which the concept of MID
seems useful and investigators should derive it from
patients. First, it appears easily understood by clinicians
and investigators as a key concept when one considers the
problem of interpretability of PRO scores. Second, it
emphasizes the primacy of the patient's perspective and
implicitly links that perspective to that of the interpreta-
tion by clinicians. Third, the choice of what constitutes a
MID will inform judgments about the successfulness of an
intervention. Fourth, it helps estimating the required sam-
ple size of clinical trials, and the very design of these stud-
ies. Fifth, an individual patient achieving the score equal
or greater than the MID might be considered a beneficiary
of the intervention, what would lead to the definition of a
responder, as the authors of the guidance suggested. How-
ever, one should be cautious as it is certain that the MID
varies across patients and possibly also across patient
groups [16]. Since the MIDs are usually derived from the
groups of patients, the description of responders based on
the MID should be used with great care and with full dis-
closure to readers how it was obtained.
How does one estimate the MID?
Unfortunately, there is no "gold standard" methodology
of achieving the meaningfulness of PRO scores, estimat-
ing the MID, or interpreting these scores. This is part of the
reason why interpreting PRO measures is indeed a
demanding task. A possible and widely used technique
would be to approach a group of experts and ask them
whether the particular PRO score looks like a reasonable
measure of what is important to patients, as they perceive
it. This technique may be termed analogous to face valid-
ity. However, as described above this approach is based
solely on the opinion of experts, and because the experts'
perception of what is important to patients tends not to
mirror what in fact it is [11,15], this method must he
regarded as a weak means to establish a score that would
represent the MID for patients. Fortunately, less medico-
centric techniques are available, although none of them is
perfect. The authors of the FDA guidance name four exam-
ples of derivation of the MID: "mapping changes in PRO
scores to clinically relevant and important changes in
non-PRO measures of treatment outcome", "mapping
changes in PRO scores to other PRO scores", "using an
empirical rule", and "using a distribution-based
approach". We think the users of the guidance would ben-
efit from some explanation added to this presentation by
giving specific examples or descriptions.
Patient versus population perspective
An important issue in shaping the interpretability of a
PRO score is whether one makes inferences about patient
important change with respect to individuals or popula-
tions [17]. One frequently distinguishes between the sig-
nificance of a particular change in score in an individual
patient and a change of the same magnitude in the mean
score of a group of patients [18]. From the point of view
of the individual, a worthwhile change may be the one
that results in a meaningful reduction in symptoms or
improvement in function. In contrast, a change in mean
score of a magnitude that would be trivial in an individual
(e.g., 2 mm Hg reduction in blood pressure), may trans-
late into a large number of benefiting patients in a popu-
lation (e.g. reduced strokes).
There are two reasons for this difference in interpretation.
First, one might consider particular change in score (e.g. 2
mm Hg in blood pressure) in an individual trivial, that is
within the error of measurement. In this sense, the change
is trivial because one does not believe it is real. On the
contrary, relatively modest improvements at the individ-
ual level may be rated as important when considered at
the group level. The second reason for the distinction
between interpretation of individual and group differ-
ences is that not every individual in the population does
experience the same change in outcome – even groups
with negligible mean changes in PRO scores (or any out-
come expressed as a mean score) are likely to contain indi-
vidual patients whose improvement is noteworthy and
leads to a reduced stroke risk [19]. From the group per-
spective individual variability is considered random vari-
ation associated with a measurement error. Therefore,
from the individual patient perspective this very variabil-
ity in individual response highlights the fundamental
deficiency of summarizing treatment effects as a differ-
ence in means. Let us assume there is a threshold below
which any change in status has no important conse-
quences for the patient (i.e. the MID), and mean change
in a group is below that threshold. If the distribution of
change with treatment is narrow, it is possible that no
patient will achieve an important benefit with treatment.
On the other hand, if the distribution of change is large, it
is likely that a substantial number of patients may achieve
a benefit.
Inferences at the group or population level are likely to be
informative with respect to the decisions regarding health
care policy and inferences at the level of an individual areHealth and Quality of Life Outcomes 2006, 4:69 http://www.hqlo.com/content/4/1/69
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most relevant to the decisions concerning the manage-
ment of individual patients.
Regardless of the chosen perspective, investigators have
used two easily separable strategies to achieve an under-
standing of the meaning of scores of a given instrument
[18]. The first relies on anchor-based methods and exam-
ines the relationship between scores on the target instru-
ment (the instrument for which interpretation is in
question) and some independent measure, termed an
anchor. The FDA guidance refers to this strategy as "map-
ping". The second strategy is based on the statistical char-
acteristics of the obtained PRO scores and is termed
distribution-based. These later methods differ from
anchor-based approaches in that they interpret results in
terms of the relation between the magnitude of effect and
some measure of variability in results.
For an in-depth review of these methods we refer the
Readers to the work by Crosby [20] and Guyatt [17].
Herein we will present only the most general aspects of
anchor- or distribution-based approaches.
Anchor-based approaches to estimating a meaningful change in PRO 
measure
Anchor-based methods compare PRO measures to an
anchor that is itself interpretable, i.e. has a known rele-
vance to patients. For example, a global rating of change
[21-24], status on an important and easily understood
measure of function [25], the presence of symptoms [26],
mean scores of patients with a particular diagnosis [27-
30], disease severity [31], response to treatment [31,32],
or the prognosis of future events such as mortality
[26,33,34], job loss [26,35,36] or health care utilization
[37] can provide a useful anchor. Anchor-based methods
require at least moderate correlation of the change on the
anchor with the change on the target instrument.
One can subclassify anchor-based approaches into those
that solve the interpretability problem in a single step –
presenting population differences in status on multiple
anchors – which one may call a population-focused
approach, and those, that require two separate steps – first
establishing the MID and then examining the proportion
of patients who achieved the MID – which one may call
an individual-focused approach.
The population-focused approach classifies patients in
terms of the population to which they belong and is anal-
ogous to establishing construct validity, in that multiple
anchors are generally required. In contrast, the individual
patient-focused strategy tends to focus on a single anchor
that is usually designed to establish a MID, but not neces-
sarily so. This approach is analogous to criterion validity.
Those taking the individual patient-based approach usu-
ally attempt to identify a threshold between a change in
score that is trivial and a change that is important (i.e. the
MID). Those taking the population-based approach most
commonly avoid identifying such a threshold, but offer
relationships between target measure and multiple
anchors instead, implicitly acknowledging that the thresh-
old may vary, depending on the population under study
and the range and severity of the problems being meas-
ured by the PRO instrument in question.
Having chosen a single-anchor approach, investigators
may use alternative analytic strategies that will lead to dif-
ferent estimates of the MID [38]. The simplest and so far
most widely used approach is to specify a result or a range
of anchor instrument results that correspond to the MID
and calculate the target score matching that value. The
commonly used alternative is the use of receiver operating
characteristic curves adopted from diagnostic testing [39-
41]. This strategy classifies each patient according to the
anchor instrument as experiencing an important change
or not experiencing such a change. Investigators then test
a series of cut-off points to determine the number of mis-
classifications. These misclassifications correspond to
false-positive results (patients mistakenly categorized as
changed) and false-negative results (patients mistakenly
categorized as unchanged). The optimal cut-off point will
minimize the number of misclassifications.
Distribution-based approaches to estimating a meaningful change in 
PRO score
Distribution-based methods interpret results in terms of
the relation between the magnitude of effect and some
measure of variability in results. Three categories of distri-
bution-based approaches can be recognized [20]. The first
approach depends on statistical significance and rates the
score change in relation to the probability that this change
is a result of a random variation of scores. Paired t-statistic
[42] and growth curve analysis [43] are the examples. A
second approach evaluates the score change in relation to
sample variation: baseline standard deviation of patients
[44,45], variation of change scores [24], and variation of
change scores in a stable group [46]. The third approach
evaluates the score change in relation to measurement
precision. Examples include standard error of the mean
[47] and a reliable change index [48]. As a measure of var-
iability, investigators may choose between-patient varia-
bility (for example, the standard deviation of patients at
baseline) or within-patient variability (for example, the
standard deviation of change in the PRO that patients
experienced during a study).
The most widely used distribution-based method is the
between-person standard deviation, often referred to as
effect size [44,45]. The group from which it is drawn isHealth and Quality of Life Outcomes 2006, 4:69 http://www.hqlo.com/content/4/1/69
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typically the control group at baseline or the pooled
standard deviation of the experimental and control
groups at baseline. Cohen [44] provided a rough rule of
thumb to interpret the magnitude of the effect sizes.
Changes in the range of 0.2 standard deviation units rep-
resent small changes, 0.5 – moderate changes, and 0.8 –
large changes. Some recent empirical studies suggest that
Cohen's guideline may in fact be generally applicable
[49], but other authors propose that the MID is in the
range of 0.2 to 0.5 standard deviation unit [50] or corre-
sponds with an effect size of 0.5 [51,52].
The advantage of distribution-based methods is that the
values are easy to generate in contrast with the work
needed to generate an anchor-based interpretation. These
methods have two basic limitations: estimates of variabil-
ity differ from study to study and there is no intuitive
meaning of the effect size (standard deviation units).
How does the MID help to make sense of the results of 
clinical trials?
Describing the choice of the methods for interpretation of
PRO instruments the authors of the FDA guidance
addressed only the issue of deriving the MID leaving the
issue of the very interpretation of clinical trial results
based on these instruments unanswered. We have advo-
cated that dichotomizing the results of a PRO measure
facilitates interpretation of the clinical trial utilizing
HRQL instruments [53,54]. Considering the above
described approaches to achieve meaningfulness of PRO
scores it is evident that one does not have to estimate the
MID to grasp the meaning of particular scores.
Dichotomizing the distribution of scores
We have argued that one possibility is the use of intuitive
thresholds to interpret PRO scores. To facilitate interpret-
ability of clinical trial results, researchers can report
thresholds that either refer to an absolute score (e.g. one
can consider patients above a certain score as having
achieved the outcome) or a change in score (e.g. one can
consider patients' PRO measure as having improved or
deteriorated if they achieve a certain change in score). For
the absolute score, while interpreting the results of a trial,
one could consider the proportion of patients who
achieve a given mean score for which anchors exist before
and after an intervention. For the change score approach,
one could consider the proportion of patients who have
changed by a certain score, for instance of 10. Researchers
may report the results as a categorized distribution of the
proportion of patients who achieved certain improve-
ment in PRO measure. We also argued that using the
example of the SF-36 instrument from the Medical Out-
comes Study [55], the proportion of patients who are able,
according to scores on the Physical Function scale (range
0–100), to walk a distance of one block (approximately
100 meters) without difficulty would be 32% for a score
of 40, 50% for a score of 50, and 79% for a score of 60.
Increasing the score from 40 to 50 indicates that 18%
more people state that they can walk without serious lim-
itations, and increasing it from 50 to 60 – that 29% more
can walk one block, etc. From the group perspective, one
could interpret a score of 50 as corresponding to approxi-
mately 50% of patients being able to walk one block.
From an individual patient perspective, a score of 50 indi-
cates a 50% chance that the patient is able to walk one
block. If an intervention improved this score to 60, there
would now be a 79% chance, or a 29% increase, of this
patient's ability to walk one block. This interpretation is
based on the assumption that the patient has similar char-
acteristics to the population from whom these values are
obtained.
Interpretation aids
Another example for the use of content-based interpreta-
tion of PRO measures is the construction of interpretation
aids. Valderas et al. applied a specific model of item
response theory (IRT) to an instrument measuring per-
ceived visual function, the Visual Function Index (VF-14)
[56]. This instrument asks respondents to rate the difficul-
ties they have with their vision during performance of 14
everyday activities. Valderas et al. developed simple inter-
pretation aids, that may facilitate the understanding of a
particular score. The items were ordered according to their
difficulty and used in the construction of a 'ruler' aid. This
aid indicates the expected performance of an average
patient with a given score. The authors have chosen a VF-
14 score at which 50% of respondents have no difficulty
performing a given task. For instance, a score of 97 indi-
cates that 50% of respondents can drive without difficulty
at night in regard to their visual function. A score of 75
indicates that 50% of respondents have no difficulty read-
ing small print, 48 – watching TV and seeing steps, 36 –
recognizing people when they are close, etc. Obviously,
the authors could have chosen a score at which any other
proportion of respondents has no difficulty performing a
given task, but using a cut-off of 50% simplifies interpre-
tation because it implies a 1 to 1 chance. This method of
developing interpretation aids could be applied to many
other PRO instruments. The important contribution of
interpretation aids developed utilizing the IRT is that it
informs clinicians and patients what performance they
can expect based on a score on a multi-item instrument.
The MID
Irrespective of the strategy used to estimate the MID, from
the individual patient point of view it is relevant to
present the clinical trial results as the proportion of
patients achieving a particular benefit (e.g. a MID, or any
other value for that matter, be it a small, moderate, or
large difference), instead of reporting only a mean differ-Health and Quality of Life Outcomes 2006, 4:69 http://www.hqlo.com/content/4/1/69
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ence. To calculate the proportion who achieved a MID,
one must consider not only the difference between groups
in those who achieve that improvement but also the dif-
ference between groups in those who deteriorate by the
same amount. These differences can also be transformed
into a number needed to treat required to achieve an MID
in one patient after a given time period.
Conclusion
Estimation of an MID and interpretation of clinical trial
results that present patient important outcomes is as
demanding as it is vital in informing the decision to rec-
ommend or not to recommend or approve a given inter-
vention. Investigators should be encouraged to use
reliable and valid methods to achieve meaningfulness of
their results, preferably those that rely on patients to esti-
mate the MID. Ideally, the different approaches to esti-
mating the MID will produce similar results. If they do
not, this should be explicitly labelled. The FDA will have
to provide more specific guidance than what is offered in
the current document as to which methods and
approaches are preferred. Clinical investigators will bene-
fit from such advice, since it will let them avoid designing
or selecting approaches that are likely not to be valid and,
therefore, not accepted by the regulators. We hope that
patient-based approaches will prevail as the perspective of
the patients or their informed proxies for conditions that
render patient decisions difficult (e.g. end of life deci-
sions). At a minimum all approaches should be patient-
driven and involve scenarios and vignettes, but not solely
a clinician's judgment. We agree with the authors of the
parallel comment that demonstrating responsiveness is a
key component of demonstrating appropriate measure-
ment properties an instrument [57]. We believe the MID
of a generic instrument, however, should not vary by pop-
ulation and context because it questions the use of the
PRO measure as a generic instrument [9]. In regards to
reporting of PRO measures it is advisable that investiga-
tors report the proportion of patients achieving that ben-
efit.
Competing interests
HJS and GHG are authors of the CRQ. McMaster Univer-
sity and a research account used by HJS and GHG receive
licensing fees from the use of the CRQ. There are no other
competing interests related to this work.
Authors' contributions
JB and HJS developed an outline of this article based on
many discussions with GG. JB wrote the first draft of the
article and HJS and GG critically revised it.
References
1. Federal Drug Administration: Guidance for Industry. Patient-
Reported Outcome Measures: Use in Medical Product
Development to Support Labeling Claims.   [http://
www.fda.gov/cder/guidance/5460dft.pdf].
2. Feinstein AR: Indexes of contrast and quantitative significance
for comparisons of two groups.  Stat Med 1999,
18(19):2557-2581.
3. Naylor CD, Llewellyn-Thomas HA: Can there be a more patient-
centred approach to determining clinically important effect
sizes for randomized treatment trials?  J Clin Epidemiol 1994,
47(7):787-795.
4. Bobbio M, Demichelis B, Giustetto G: Completeness of reporting
trial results: effect on physicians' willingness to prescribe.
Lancet 1994, 343(8907):1209-1211.
5. Hux JE, Levinton CM, Naylor CD: Prescribing propensity: influ-
ence of life-expectancy gains and drug costs.  J Gen Intern Med
1994, 9(4):195-201.
6. Naylor CD, Chen E, Strauss B: Measured enthusiasm: does the
method of reporting trial results alter perceptions of thera-
peutic effectiveness?  Ann Int Med 1992, 117(11):916-921.
7. Redelmeier DA, Tversky A: Discrepancy between medical deci-
sions for individual patients and for groups.  New Engl J Med
1990, 322(16):1162-1164.
8. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related
quality of life.  Ann Int Med 1993, 118(8):622-629.
9. Schünemann HJ, Guyatt GH: Commentary – goodbye M(C)ID!
Hello MID, where do you come from?  Health Serv Res 2005,
40(2):593-597.
10. Schünemann HJ, Puhan M, Goldstein R, Jaeschke R, Guyatt GH:
Measurement Properties and Interpretability of the Chronic
Respiratory Disease Questionnaire (CRQ).  J COPD 2005,
2:81-89.
11. Puhan MA, Behnke M, Devereaux PJ, Montori VM, Braendli O, Frey
M, Schünemann HJ: Measurement of agreement on health-
related quality of life changes in response to respiratory
rehabilitation by patients and physicians – a prospective
study.  Respir Med 2004, 98(12):1195-1202.
12. Sneeuw KC, Sprangers MA, Aaronson NK: The role of health care
providers and significant others in evaluating the quality of
life of patients with chronic disease.  J Clin Epidemiol 2002,
55(11):1130-1143.
13. Ubel PA, Loewenstein G, Jepson C: Whose quality of life? A com-
mentary exploring discrepancies between health state eval-
uations of patients and the general public.  Qual Life Res 2003,
12(6):599-607.
14. von Essen L: Proxy ratings of patient quality of life – factors
related to patient-proxy agreement.  Acta oncologica (Stockholm,
Sweden) 2004, 43(3):229-234.
15. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ,
Brownell BF, Nagpal S, Cox JL: Differences between perspectives
of physicians and patients on anticoagulation in patients with
atrial fibrillation: observational study.  BMJ 2001,
323(7323):1218-1222.
16. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL: What
are minimal important changes for asthma measures in a
clinical trial?  Eur Respir J 1999, 14(1):23-27.
17. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR: Meth-
ods to explain the clinical significance of health status meas-
ures.  Mayo Clin Proc 2002, 77(4):371-383.
18. Lydick E, Epstein RS: Interpretation of quality of life changes.
Qual Life Res 1993, 2(3):221-226.
19. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar
D: Determining clinically important differences in health sta-
tus measures: a general approach with illustration to the
Health Utilities Index Mark II.  PharmacoEcon 1999,
15(2):141-155.
20. Crosby RD, Kolotkin RL, Williams GR: Defining clinically mean-
ingful change in health-related quality of life.  J Clin Epidemiol
2003, 56(5):395-407.
21. Deyo RA, Inui TS: Toward clinical applications of health status
measures: sensitivity of scales to clinically important
changes.  Health Serv Res 1984, 19(3):275-289.
22. Jaeschke R, Singer J, Guyatt GH: Measurement of health status.
Ascertaining the minimal clinically important difference.
Contr Clin Trials 1989, 10(4):407-415.
23. Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a mini-
mal important change in a disease-specific Quality of Life
Questionnaire.  J Clin Epidemiol 1994, 47(1):81-87.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2006, 4:69 http://www.hqlo.com/content/4/1/69
Page 7 of 7
(page number not for citation purposes)
24. Stucki G, Liang MH, Fossel AH, Katz JN: Relative responsiveness
of condition-specific and generic health status measures in
degenerative lumbar spinal stenosis.  J Clin Epidemiol 1995,
48(11):1369-1378.
25. Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr:
The cost effectiveness of auranofin: results of a randomized
clinical trial.  J Rheumatol 1988, 15(1):35-42.
26. Ware JE, Keller SD: Interpreting general health measures.  In
Quality of Life and Pharmacoeconomics in Clinical Trials Edited by: Spilker
B. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:445-460. 
27. Brooks WB, Jordan JS, Divine GW, Smith KS, Neelon FA: The
impact of psychologic factors on measurement of functional
status. Assessment of the sickness impact profile.  Med Care
1990, 28(9):793-804.
28. Deyo RA, Inui TS, Leininger JD, Overman SS: Measuring functional
outcomes in chronic disease: a comparison of traditional
scales and a self-administered health status questionnaire in
patients with rheumatoid arthritis.  Med Care 1983,
21(2):180-192.
29. Fletcher A, McLoone P, Bulpitt C: Quality of life on angina ther-
apy: a randomised controlled trial of transdermal glyceryl
trinitrate against placebo.  Lancet 1988, 2(8601):4-8.
30. McSweeny AJ, Grant I, Heaton RK, Adams KM, Timms RM: Life
quality of patients with chronic obstructive pulmonary dis-
ease.  Arch Intern Med 1982, 142(3):473-478.
31. King MT: The interpretation of scores from the EORTC qual-
ity of life questionnaire QLQ-C30.  Qual Life Res 1996,
5(6):555-567.
32. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The Sickness
Impact Profile: development and final revision of a health
status measure.  Med Care 1981, 19(8):787-805.
33. Mossey JM, Shapiro E: Self-rated health: a predictor of mortal-
ity among the elderly.  Am J Pub Health 1982, 72(8):800-808.
34. Idler EL, Angel RJ: Self-rated health and mortality in the
NHANES-I Epidemiologic Follow-up Study.  Am J Pub Health
1990, 80(4):446-452.
35. Brook RH, Ware JE Jr, Rogers WH, Keeler EB, Davies AR, Donald
CA, Goldberg GA, Lohr KN, Masthay PC, Newhouse JP: Does free
care improve adults' health? Results from a randomized con-
trolled trial.  New Engl J Med 1983, 309(23):1426-1434.
36. Fayers PM, Machin D: Quality of life: assessment, analysis and
interpretation.  Chichester: John Wiley & Sons; 2000. 
37. Ware JE Jr, Manning WG Jr, Duan N, Wells KB, Newhouse JP:
Health status and the use of outpatient mental health serv-
ices.  Am Psychol 1984, 39(10):1090-1100.
38. Brant R, Sutherland L, Hilsden R: Examining the minimum
important difference.  Stat Med 1999, 18(19):2593-2603.
39. Deyo RA, Centor RM: Assessing the responsiveness of func-
tional scales to clinical change: an analogy to diagnostic test
performance.  J Chron Dis 1986, 39(11):897-906.
40. Stratford PW, Binkley JM, Riddle DL, Guyatt GH: Sensitivity to
change of the Roland-Morris Back Pain Questionnaire: part
1.  Phys Ther 1998, 78(11):1186-1196.
41. Ward MM, Marx AS, Barry NN: Identification of clinically impor-
tant changes in health status using receiver operating char-
acteristic curves.  J Clin Epidemiol 2000, 53(3):279-284.
42. Husted JA, Cook RJ, Farewell VT, Gladman DD: Methods for
assessing responsiveness: a critical review and recommenda-
tions.  J Clin Epidemiol 2000, 53(5):459-468.
43. Speer DC, Greenbaum PE: Five methods for computing signifi-
cant individual client change and improvement rates: sup-
port for an individual growth curve approach.  J Consul Clin
Psychol 1995, 63(6):1044-1048.
44. Cohen J: Statistical Power Analysis for the Behavioral Sci-
ences.  2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates;
1988. 
45. Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting
changes in health status.  Med Care 1989, 27(3 Suppl):S178-189.
46. Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-spe-
cific quality of life in clinical trials.  CMAJ 1986, 134(8):889-895.
47. Wyrwich KW, Tierney WM, Wolinsky FD: Further evidence sup-
porting an SEM-based criterion for identifying meaningful
intra-individual changes in health-related quality of life.  J Clin
Epidemiol 1999, 52(9):861-873.
48. Jacobson NS, Truax P: Clinical significance: a statistical
approach to defining meaningful change in psychotherapy
research.  J Consul Clin Psychol 1991, 59(1):12-19.
49. Redelmeier DA, Guyatt GH, Goldstein RS: Assessing the minimal
important difference in symptoms: a comparison of two
techniques.  J Clin Epidemiol 1996, 49(11):1215-1219.
50. Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the sig-
nificance of changes in health-related quality-of-life scores.  J
Clin Oncol 1998, 16(1):139-144.
51. Best WR, Becktel JM: The Crohn's disease activity index as a
clinical instrument.  In Developments in Gastroenterology: Recent
Advances in Crohn's Disease Edited by: Pena AS, Weterman IT, Booth
C, Strober W. Dordrecht, the Netherlands: Martinus Nijhoff;
1981:7-12. 
52. Redelmeier DA, Guyatt GH, Goldstein RS: On the debate over
methods for estimating the clinically important difference.  J
Clin Epidemiol 1996, 49(11):1223-1224.
53. Schünemann HJ, Akl EA, Guyatt GH: Interpreting the Results of
Patient Reported Outcome Measures in Clinical Trials: The
Clinician's Perspective.  Health Qual Life Outcomes 2006, 4:62.
54. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS: Inter-
preting treatment effects in randomised trials.  BMJ Clinical
research ed 1998, 316(7132):690-693.
55. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD,
McGlynn EA, Ware JE Jr: Functional status and well-being of
patients with chronic conditions. Results from the Medical
Outcomes Study.  JAMA 1989, 262(7):907-913.
56. Valderas JM, Alonso J, Prieto L, Espallargues M, Castells X: Content-
based interpretation aids for health-related quality of life
measures in clinical practice. An example for the visual func-
tion index (VF-14).  Qual Life Res 2004, 13(1):35-44.
57. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson
NK: Responsiveness and minimal important differences for
patient reported outcomes.  Health Qual Life Outcomes 2006,
4:70.